Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: Comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)

Pathology International

Volumn 62, Issue 11, 2012, Pages 728-734

  Kiyose, Shinichiro ^a,c   Igarashi, Hisaki ^a   Nagura, Kiyoko ^a   Kamo, Takaharu ^a   Kawane, Kazunori ^b   Mori, Hiroki ^b   Ozawa, Takachika ^b   Maeda, Matsuyoshi ^d   Konno, Keisuke ^c   Hoshino, Hideaki ^c   Konno, Hiroyuki ^a   Ogura, Hiroyuki ^a   Shinmura, Kazuya ^a   Hattori, Naohiko ^c   Sugimura, Haruhiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU MEDICAL CENTER   (Japan)

^c JOKOH CoLtd   (Japan)

^d TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Breast cancer; Chromogenic in situ hybridization (CISH); Fluorescence in situ hybridization (FISH); Gastric cancer; HER2; Immunohistochemistry (IHC)

Indexed keywords

ARTICLE; BREAST CANCER; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 17; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; HER2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; STOMACH CANCER; TISSUE MICROARRAY;

BREAST NEOPLASMS; FEMALE; FORMALDEHYDE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84868336008     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2012.02862.x     Document Type: Article

References (24)

1. Yamamoto T, Ikawa S, Akiyama T etal. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230-34.
2. Yokota J, Yamamoto T, Toyoshima K etal. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986; 1: 765-7.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
4. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11: 1936-42.
5. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-28.
6. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: A novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 2002; 82: 1007-14.
7. Arnould L, Denoux Y, MacGrogan G etal. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003; 88: 1587-91.
8. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004; 10: 4793-8.
9. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: Does it measure up to fluorescence in situ hybridization? Am J Clin Pathol 2005; 123: 237-43.
10. Sugimura H. Detection of chromosome changes in pathology archives: An application of microwave-assisted fluorescence in situ hybridization to human carcinogenesis studies. Carcinogenesis 2008; 29: 681-7.
11. Sugimura H, Mori H, Nagura K etal. Fluorescence in situ hybridization analysis with a tissue microarray: 'FISH and chips' analysis of pathology archives. Pathol Int 2010; 60: 543-50.
12. Shinmura K, Goto M, Suzuki M etal. Reduced expression of MUTYH with suppressive activity against mutations caused by 8-hydroxyguanine is a novel predictor of a poor prognosis in human gastric cancer. J Pathol 2011; 225: 414-23.
13. Yan B, Yau EX, Bte Omar SS etal. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010; 63: 839-42.
14. Park DI, Yun JW, Park JH etal. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-9.
15. Moelans CB, Milne AN, Morsink FH, Offerhaus GJA, vanDienst PJ. Low frequency of HER2 amplification and overexpression in early onse gastric cancer. Cell Oncol 2011; 34: 89-95.
16. Tsuda H, Akiyama F, Terasaki H etal. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 2001; 92: 2965-74.
17. Takehana T, Kunitomo K, Kono K etal. Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833-7.
18. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010; 78: 26-33.
19. Bang YJ, Chung H, Xu J. Pathological features of advanced gastric cancer (GC): Relationshi to human epideral growth factor receptor 2 (HER2) positivity in the global sreening programme of the ToGA trial. J Clin Oncol 2009; 27: abstr 4556.
20. Isola J, Tanner M. Chromogenic in situ hybridization in tumor pathology. Methods Mol Med 2004; 97: 133-44.
21. Kiyose S, Nagura K, Tao H etal. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int 2012; 62: 477-84.
22. Meng H, Chen R, Li W, Xu L. Correlations of TOP2A gene aberrations and expression of topoisomerase IIalpha protein and TOP2A mRNA expression in primary breast cancer: A retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. Pathol Int 2012; 62: 391-9.
23. Natsume H, Shinmura K, Tao H etal. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med 2012; 10: 97.
24. Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Pathol Int 2011; 60: 510-15.